Sales turn-over of Quinidine Sulphate etc.

1507. SHRIMATI RATAN KUMARI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Quinidine Sulphate, Dopamine, Ergometrine, Flurazepam, Glycerol Trinitrate, Heptatis-B-Vaccine have been covered under the Drugs Price Control Order, 1987 on the basis of recommendations of the Kelkar Committee;

(b) whether it is also a fact that the sales turn-over of these drugs is negligible;

(c) whether it is also a fact that Oxyphenonium Bromide, Propatheline Bromide, Avapyrazone, Catopril, Bisacodyl, Meclizine Hcl and Dimenhydrinate have been excluded from price control;

(d) whether it is also a fact that sales turn-over of these drugs is significant and growing; and

(e) what is the basis for inclusion and exclusion of these drugs from price control and what was the sales turn-over of each during 1986?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) and (c) Yes, Sir.

(b) and (d) Sales turn-over of bulk drugs/formulations is not monitored.

(e) Bulk drugs referred to in part (a) of the question have been included in the list of Category II drugs for price control on the recommendation of the Kelkar Committee, while the bulk drugs referred to in part (c) of the question were not included by the committee in the said list.

Exemption from price control of single ingredient finished medicines

1508. SHRIMATI RATAN KUMARI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Government have exempted single ingredient finished medicines being marketed under generic name from price control;

(b) whether it is also a fact that Government have also exempted certain single ingredient finished medicines under brand names;

(c) if so, what are the names of those medicines and on what specific criteria these medicines have been exempted from price control; and

(d) what are the reasons for controlling the prices of other medicines on a single drug being marketed under brand names?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) and (c) All Vitamin single ingredient formulations either in brand names or generic names are exempt from price control under DPCO, 1987.

(d) The Kelkar Committee had recommended exemption from price control of all single ingredient formulations in generic name but in the case of Vitamins, the Committee recommended decontrol of all single ingredient formulations irrespective of whether these were under generic name or brand name.

Vaccines excluded from price control list

1509. SHRIMATI RATAN KUMARI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Government had stated in a press state-